Addiction

Odyssey Behavioral Healthcare’s 2023 Clinical Outcomes Report Identifies Notable Symptom Improvement From Treatment

BRENTWOOD, TN / ACCESSWIRE / July 16, 2024 / Odyssey Behavioral Healthcare ("Odyssey"), a leading provider of mental health, addiction,…

2 years ago

Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference

Vancouver, Canada, July 12, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

2 years ago

Achieve Life Sciences to Present at JonesHealthcare Seaside Summit 2024

SEATTLE and VANCOUVER, British Columbia, July 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…

2 years ago

Alleva Recognized in Software Advice FrontRunners for HIPAA Compliance Software Report 2024

LAGUNA NIGUEL, Calif., July 2, 2024 /PRNewswire/ -- Alleva, a premier provider of electronic medical record (EMR) software solutions tailored…

2 years ago

Hazelden Betty Ford Foundation Announces Lineup for 75th Anniversary Gala

Rob Lowe to EmceeCenter City, Minnesota--(Newsfile Corp. - July 1, 2024) - On Friday, September 13, Hazelden Betty Ford Foundation,…

2 years ago

Achieve Life Sciences Announces Addition to the U.S. Russell 3000® and Russell Microcap® Indexes

SEATTLE and VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical…

2 years ago

Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment

Vancouver, Canada, June 28, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

2 years ago

I’m Lonely, Inc. Launches Revolutionary Dating App to Foster Genuine In-Person Connections

HOUSTON, June 27, 2024 /PRNewswire/ -- I'm Lonely, Inc. is thrilled to announce the launch of its innovative dating app, designed…

2 years ago

Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160

Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using…

2 years ago

Safe Supply Streaming Corp. Announces Resignation of Board Member

Toronto, Ontario--(Newsfile Corp. - June 21, 2024) - Safe Supply Streaming Co Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe Supply" or…

2 years ago